Treatment options for progression or recurrence of glioblastoma: a network meta-analysis-Reference-Cited by-同舟云学术

Treatment options for progression or recurrence of glioblastoma: a network meta-analysis

Published:2021-01-05 Issue:5 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

McBain Catherine¹²,Lawrie Theresa A³,Rogozińska Ewelina³,Kernohan Ashleigh⁴,Robinson Tomos⁴,Jefferies Sarah⁵

Affiliation:

1. Clinical Oncology; The Christie NHS FT; Manchester UK

2. Geoffrey Jefferson Brain Research Centre; Manchester UK

3. The Evidence-Based Medicine Consultancy Ltd; Bath UK

4. Population Health Sciences Institute; Newcastle University; Newcastle upon Tyne UK

5. Department of Oncology; Addenbrooke's Hospital; Cambridge UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference232 articles.

1. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution;Azoulay;Journal of Neuro-oncology,2017

2. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma;Batchelor;Journal of Clinical Oncology,2013

3. Alliance a071101: a phase II randomized trial comparing the efficacy of heat shock protein peptide complex-96 (HSPPC-96) vaccine given with bevacizumab versus bevacizumab alone in the treatment of surgically resectable recurrent glioblastoma;Bloch;Neuro-oncology,2017

4. A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma;Brandes;Journal of Clinical Oncology,2015

5. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma;Brandes;Neuro-oncology,2016

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bibliometric Analysis to Improve Combined Treatment Strategies for Glioblastoma in America;Current Cancer Therapy Reviews;2024-11

2. EGFLAM exhibits oncogenic activity and shows promise as a prognostic biomarker and therapeutic target in glioblastoma;International Immunopharmacology;2024-09

3. TMEM17 Promotes Tumor Progression in Glioblastoma by Activating the PI3K/AKT Pathway;Frontiers in Bioscience-Landmark;2024-08-16

4. Recurrent High-Grade Glioma: Multiple Surgeries and Reirradiation;Journal of Medical and Radiation Oncology;2024-07-27

5. Zonulin as Gatekeeper in Gut–Brain Axis: Dysregulation in Glioblastoma;Biomedicines;2024-07-24